# Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

> **NCT07552558** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 45 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma
- HPV-Negative Squamous Cell Carcinoma

## Interventions

- **RADIATION:** Hypofractionated Stereotactic Body Radiotherapy (SBRT)
- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Ficerafusp alfa

## Key facts

- **NCT ID:** NCT07552558
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2028-08-31
- **Final completion:** 2033-08-31
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-04-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07552558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07552558, "Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT07552558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*